Verana Health Funding, Investors & Competitors

Verana Health has raised $341M across 6 funding rounds, most recently a $52M undisclosed-stage round in January 2026.

Last Verana Health funding round

$52M

Undisclosed stage · Jan 2026

Cumulative funding Verana Health raised

$341M

across 6 funding rounds

Key investors in Verana Health

  • GV
  • Casdin Capital
  • GE Ventures
  • Biomatics Capital Partners
  • Brook Byers
  • Lagunita BioSciences
  • Bain Capital Ventures
  • Novo Holdings

Verana Health Overview

About Verana Health

Verana Health is a San Francisco-headquartered digital health company that aggregates and analyzes real-world data from over 20,000 providers across 70 electronic health record systems. Exclusively partnered with medical societies like the American Academy of Ophthalmology, it powers the VeraQ engine for AI-enhanced insights from nearly half a billion patient encounters. Verana's Qdata datasets support life sciences firms in clinical research, evidence generation, and quality improvement for ophthalmology, urology, and gastroenterology specialties.


Founded

2008

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Licensing

Verana Health Funding History

Verana Health has raised a total of $341M across 6 funding rounds.

Verana Health's first fundraising round was a $1M Series A in January 2013. The most recent completed round was a $52M undisclosed-stage round in January 2026.

Verana Health funding rounds

Verana Health funding rounds
DateStageInvestorsRaisedDeal Summary
Jan 2026Undisclosed stage-$52MVerana Health is a digital health company providing real-world data (RWD) and insights for drug lifecycle and medical practice from partnerships with medical societies like the American Academy of Ophthalmology's IRIS Registry and American Urological Association's AUA Quality Registry. It serves life sciences companies for clinical trials, regulatory submissions, and health economics. In January 2022, it raised $150M in a Series E round led by Johnson & Johnson Innovation–JJDC and Novo Growth, with participation from GV, Casdin Capital, Brook Byers, Merck Global Health Innovation Fund, THVC, and Breyer Capital, to advance products, enhance provider value, and expand data partnerships. Total funding raised is reported as $366.5M or $364.32M across rounds. Verana Health merged with COTA, an oncology RWD provider, to expand into cancer data from academic medical centers, accessing over 95 million patients, 20,000 clinicians, and 10 million oncology patients, serving 17 of the top 20 global biopharma companies. The merger included $52M in new equity from existing investors; it enhances AI-driven curation across ophthalmology, urology, neurology, and oncology for regulatory and evidence generation. In 2025, Frost & Sullivan named it a Growth and Innovation Leader in Life Sciences RWE solutions for its clinically rich data platform VeraQ. The company collaborates with pharma like Janssen on R&D for prostate cancer and vision loss using de-identified registry data to reduce costs versus traditional trials, which can exceed $3B per drug. It positions as a key RWE partner post-merger, with regulatory expertise for FDA interactions.
Jan 2022Series EJohnson & Johnson Innovation (lead); Novo Holdings (lead); Breyer Capital; Transformational Healthcare; Revelation Partners; GV; Casdin Capital; Merck Global Health Innovation Fund; Brook Byers$150MVerana Health, a digital health company, raised $150 million in a Series E funding round on January 14, 2022, led by Johnson & Johnson Innovation (JJDC) and Novo Growth, the growth-stage investment arm of Novo Holdings. Existing investors GV (formerly Google Ventures), Casdin Capital, and Brook Byers participated, alongside new investors including the Merck Global Health Innovation Fund, THVC (Revelation Partners), and Breyer Capital. The funding brings the company's total capital raised to over $280-288 million, following a $100 million round in February 2020 that included the acquisition of PYA Analytics’ technology assets. Verana Health specializes in real-world clinical data analytics, leveraging an exclusive real-world data network from partnerships with three specialty medical societies: the American Academy of Ophthalmology, American Academy of Neurology, and American Urological Association. Its VeraQ platform serves as a population health data engine covering 90 million de-identified patients across 70 EHRs from over 20,000 healthcare providers, spanning seven years of data in ophthalmology, neurology, and urology. The company delivers insights for drug lifecycle management, clinical trial enablement, software-as-a-service, and real-world evidence generation, including collaborations with four of the top five pharmaceutical companies. Proceeds from the round are earmarked to advance life sciences products across the drug development process, enhance value for healthcare providers in its data network, expand data partnerships, scale clinical trial insights, and invest in AI capabilities like natural language processing for unstructured EHR data. CEO Sujay Jadhav highlighted the investors' confidence in Verana's data foundation and momentum in real-world evidence.
Feb 2020Series DGV (lead); Casdin Capital; Define Ventures; Bain Capital Ventures$100MVerana Health, a San Francisco-based digital health company, provides real-world clinical data analytics tools for physicians, leveraging de-identified patient data from registries like those of the American Academy of Ophthalmology and American Academy of Neurology. In February 2020, it closed a $100 million Series D funding round led by GV (formerly Google Ventures), with participation from Bain Capital Ventures, Casdin Capital, Define Ventures, and others including Biomatics Capital Partners. The round coincided with the acquisition of PYA Analytics' technology assets and team to enhance product development and data partnerships. The funding supported Verana's pivot from earlier focuses, enabling expansion of its VeraQ population health data engine and exclusive partnerships with medical societies. Verana structures governance with AAO and AAN CEOs on its board to align with physician missions, differentiating it in healthcare data by emphasizing physician-patient relationships. Total funding reached over $288 million by 2022, including prior rounds like a $7.8 million Series B in 2015. Subsequent developments included a $150 million Series E in January 2022 led by Johnson & Johnson Innovation and Novo Growth, with GV and Casdin participating, to advance life sciences products, enhance provider networks, and expand data partnerships. Verana collaborates with four of the top five pharmaceutical companies and maintains an exclusive real-world data network.
Jul 2018Series CGV (lead); Biomatics Capital Partners; Brook Byers; GE Ventures; Lagunita BioSciences$30MVerana Health, formerly DigiSight Technologies, is a healthcare technology company developing a platform for life science innovation using regulatory-grade specialty data sets, initially focused on ophthalmology with electronic health record (EHR) data from the American Academy of Ophthalmology’s IRIS Registry, which includes over 50 million unique patients, 211 million visits, and billions of data points. The platform supports drug and device development through investigator selection, trial design, patient targeting, and clinical insights. In July 2018, Verana Health raised $30 million in a Series C funding round led by GV (formerly Google Ventures), with participation from existing investors Biomatics Capital Partners, Brook Byers (founder of Kleiner Perkins), GE Ventures, and Lagunita Biosciences. The funding was intended to rebrand from DigiSight, expand platform capabilities, technology staff, data partnerships, and overall growth in medical informatics using real-world data. The round positioned Verana Health to advance its medical informatics platform for ophthalmology and potentially other specialties, generating deep clinical insights for patients, physicians, and pharmaceutical companies. Investors highlighted the company's potential in creating differentiated data opportunities, with GV partner Krishna Yeshwant noting its value for the industry. Brook Byers, Verana’s board chairman, praised new CEO Miki Kapoor’s track record in scaling health data companies. Following the 2018 Series C, Verana Health continued expanding, securing later rounds including a $100 million raise led by GV in an undisclosed series and a $150 million Series E in January 2022 led by Johnson & Johnson Innovation – JJDC and Novo Growth, with participation from GV, Casdin Capital, Brook Byers, and others like Merck Global Health Innovation Fund. Total funding reached approximately $288.8 million by 2022, used to enhance real-world data products, natural language processing for EHR notes, partnerships with medical societies in ophthalmology and neurology, and collaborations with top pharmaceutical companies.
Feb 2015Series BWaycross Ventures; Biomatics Capital Partners; GE Ventures; Lagunita BioSciences$8M-
Jan 2013Series A-$1M-

Who has invested in Verana Health?

15 investors have backed Verana Health across its funding rounds, including GV, Casdin Capital, GE Ventures, Biomatics Capital Partners, Brook Byers and Lagunita BioSciences.

Lead investors include Johnson & Johnson Innovation, Novo Holdings and GV.


Verana Health Investors

Investors in Verana Health by funding rounds participated
InvestorHQRoundsRoleFirst check
GVUnited StatesSan Francisco, CA3LeadJul 2018
Casdin CapitalUnited StatesNew York City, NY2ParticipantFeb 2020
Biomatics Capital PartnersUnited StatesSeattle, WA2ParticipantFeb 2015
Brook ByersUnited StatesSan Francisco, CA2ParticipantJul 2018
GE VenturesUnited StatesMenlo Park2ParticipantFeb 2015
Lagunita BioSciencesUnited StatesSan Francisco, CA2ParticipantFeb 2015
Breyer CapitalUnited StatesSan Francisco, CA1ParticipantJan 2022
Transformational HealthcareUnited StatesSan Francisco, CA1ParticipantJan 2022
Revelation PartnersUnited StatesSan Francisco, CA1ParticipantJan 2022
Waycross VenturesUnited StatesSan Francisco, CA1ParticipantFeb 2015
Novo HoldingsDenmarkCopenhagen1LeadJan 2022
Define VenturesUnited StatesSan Francisco, CA1ParticipantFeb 2020
Merck Global Health Innovation FundUnited StatesWoodcliff Lake, NJ1ParticipantJan 2022

This data is available for Pro users. Sign up to see all 15 Verana Health investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Verana Health

Verana Health has acquired 2 companies to date.

Last acquisition by Verana Health was on January 8th 2026. Verana Health acquired COTA Healthcare for undisclosed valuation.


Latest Acquisitions by Verana Health

COTA Healthcare
Data Tapestry
Description
COTA Healthcare is a New York-based real-world evidence provider for oncology founded in 2011. The company aggregates fragmented cancer patient data from electronic health records using proprietary technology and analytics. COTA delivers datasets covering treatment journeys, outcomes, and biomarkers to pharmaceutical firms and researchers advancing clinical trials and therapies.
Data Tapestry is a provider of data analytics services focused on natural language processing and healthcare applications. Based in the United States, the firm designs system architectures for predictive modeling, data integration, and NLP-driven insights. It develops strategies for linking disparate datasets, serving clients in healthcare with tools for patient outcome analysis and operational efficiency.
HQ CountryUnited StatesUnited States
HQ City
New York City, NY
Knoxville, TN
Deal Date8 Jan 20265 Feb 2020
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Verana Health acquisitions and their M&A valuation multiples.

Start Free Trial

Verana Health Competitors

Verana Health competitors include listed companies like IQVIA, Revvity, Solventum and Tempus AI, and private ones like OpenEvidence and Oura.

Public and private companies comparable to Verana Health
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
IQVIAUnited StatesUnited StatesPublicly listed$16B$3.4B$44B3.4x
RevvityUnited StatesUnited StatesPublicly listed$2.9B$735M$16B6.6x
SolventumUnited StatesUnited StatesPublicly listed$8.3B$2.5B$15B2.4x
Tempus AIUnited StatesUnited StatesPublicly listed$1.3B($131M)$15B10.1x
OpenEvidenceUnited StatesUnited StatesPrivate$100M-$12B120.0x
OuraFinlandOuluPrivate$500M-$11B22.0x

Verana Health Public Comps

Verana Health is still privately-owned, but its public comps include IQVIA, Revvity, Solventum, Tempus AI, ICON plc, Caris Life Sciences, Hinge Health, XtalPi, GeneDx and CareDx.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
IQVIA$16B$3.4B3.6x3.4x17.2x14.8x
Revvity$2.9B$735M6.5x6.6x25.4x21.0x
Solventum$8.3B$2.5B2.4x2.4x7.8x8.9x
Tempus AI$1.3B($131M)12.0x10.1x(116.0x)346.0x
ICON plc$8.3B$816M1.9x1.9x19.2x11.3x
Caris Life Sciences$812M($5M)10.3x8.7x(1640.5x)49.4x
Hinge Health$588M($522M)12.3x9.3x(13.9x)34.6x
XtalPi$120M$22M24.8x21.5x134.0x(141.6x)

This data is available for Pro users. Sign up to see all Verana Health competitors and their valuation data.

Start Free Trial

Common questions about Verana Health

When was Verana Health founded?Verana Health was founded in 2008.
Where is Verana Health headquartered?Verana Health is headquartered in San Francisco, CA, United States.
Is Verana Health publicly listed?No, Verana Health is a private, VC-backed company.
How much funding has Verana Health raised?Verana Health has raised $341M across 6 funding rounds.
What was Verana Health's last funding round?Verana Health's last funding round was a $52M undisclosed-stage round in January 2026.
Who are Verana Health's investors?Verana Health's investors include GV, Casdin Capital, Biomatics Capital Partners, Brook Byers, GE Ventures, Lagunita BioSciences, Breyer Capital, Transformational Healthcare, Revelation Partners, Waycross Ventures and 5 others.
Which companies are comparable to Verana Health?Companies comparable to Verana Health include IQVIA, Revvity, Solventum, Tempus AI, OpenEvidence and Oura.
How many companies has Verana Health acquired?Verana Health has acquired 2 companies, including COTA Healthcare and Data Tapestry.

See companies similar to Verana Health

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial